Probucol in albuminuric type 2 diabetes mellitus patients on renin-angiotensin system blockade

Sang Man Jin, Kyung Ah Han, Jae Myung Yu, Tae Seo Sohn, Sung Hee Choi, Choon Hee Chung, Ie Byung Park, Eun Jung Rhee, Sei-Hyun Baik, Tae Sun Park, In Kyu Lee, Seung Hyun Ko, You Cheol Hwang, Bong Soo Cha, Hyoung Woo Lee, Moon Suk Nam, Moon Kyu Lee

Research output: Contribution to journalArticle

4 Citations (Scopus)

Abstract

Objective - To determine the effect of probucol on urine albumin excretion in type 2 diabetes mellitus patients with albuminuria using angiotensin-converting enzyme inhibitors or angiotensin receptor blockers. Approach and Results - This was a 16-week, phase II, randomized, placebo-controlled, parallel-group study in type 2 diabetes mellitus patients with a urinary albumin/creatinine ratio of ≥300 mg/g using angiotensin-converting enzyme inhibitors or angiotensin receptor blockers, conducted in 17 tertiary referral hospitals. Eligible patients were randomized to probucol 250 mg/d (n=44), probucol 500 mg/d (n=41), and placebo (n=41) groups in a ratio of 1:1:1 after block randomization procedures, keeping the treatment assignment blinded to the investigators, patients, and study assistants. The primary end point was change in the geometric mean of urinary albumin/creatinine ratio from baseline to week 16 (ClinicalTrials.gov identifier NCT01726816). The study was started on November 8, 2012, and completed on March 24, 2014. The least squares mean change±SE from baseline in urinary albumin/creatinine ratio at week 16 was -7.2±639.5 mg/g in the probucol 250 mg/d group (n=43; P=0.2077 versus placebo group), 9.3±587.4 mg/g in the probucol 500 mg/d group (n=40; P=0.1975 versus placebo group), and 259.0±969.1 mg/g in the placebo group (n=41). Although the majority of subjects were on statins, probucol treatment significantly lowered total cholesterol and low-density lipoprotein cholesterol levels. QT prolongation occurred in one and two subjects in control and probucol 250 mg/d groups, respectively. Conclusions - Four months of probucol up to 500 mg/d failed to reduce urinary albumin excretion.

Original languageEnglish
Pages (from-to)2108-2114
Number of pages7
JournalArteriosclerosis, Thrombosis, and Vascular Biology
Volume36
Issue number10
DOIs
Publication statusPublished - 2016 Oct 1

Fingerprint

Probucol
Renin-Angiotensin System
Type 2 Diabetes Mellitus
Albumins
Placebos
Creatinine
Angiotensin Receptor Antagonists
Angiotensin-Converting Enzyme Inhibitors
Hydroxymethylglutaryl-CoA Reductase Inhibitors
Albuminuria
Random Allocation
Least-Squares Analysis
Tertiary Care Centers
LDL Cholesterol
Cholesterol
Research Personnel
Urine

Keywords

  • albuminuria
  • antioxidants
  • diabetic nephropathies
  • probucol
  • type 2 diabetes mellitus

ASJC Scopus subject areas

  • Cardiology and Cardiovascular Medicine

Cite this

Probucol in albuminuric type 2 diabetes mellitus patients on renin-angiotensin system blockade. / Jin, Sang Man; Han, Kyung Ah; Yu, Jae Myung; Sohn, Tae Seo; Choi, Sung Hee; Chung, Choon Hee; Park, Ie Byung; Rhee, Eun Jung; Baik, Sei-Hyun; Park, Tae Sun; Lee, In Kyu; Ko, Seung Hyun; Hwang, You Cheol; Cha, Bong Soo; Lee, Hyoung Woo; Nam, Moon Suk; Lee, Moon Kyu.

In: Arteriosclerosis, Thrombosis, and Vascular Biology, Vol. 36, No. 10, 01.10.2016, p. 2108-2114.

Research output: Contribution to journalArticle

Jin, SM, Han, KA, Yu, JM, Sohn, TS, Choi, SH, Chung, CH, Park, IB, Rhee, EJ, Baik, S-H, Park, TS, Lee, IK, Ko, SH, Hwang, YC, Cha, BS, Lee, HW, Nam, MS & Lee, MK 2016, 'Probucol in albuminuric type 2 diabetes mellitus patients on renin-angiotensin system blockade', Arteriosclerosis, Thrombosis, and Vascular Biology, vol. 36, no. 10, pp. 2108-2114. https://doi.org/10.1161/ATVBAHA.116.308034
Jin, Sang Man ; Han, Kyung Ah ; Yu, Jae Myung ; Sohn, Tae Seo ; Choi, Sung Hee ; Chung, Choon Hee ; Park, Ie Byung ; Rhee, Eun Jung ; Baik, Sei-Hyun ; Park, Tae Sun ; Lee, In Kyu ; Ko, Seung Hyun ; Hwang, You Cheol ; Cha, Bong Soo ; Lee, Hyoung Woo ; Nam, Moon Suk ; Lee, Moon Kyu. / Probucol in albuminuric type 2 diabetes mellitus patients on renin-angiotensin system blockade. In: Arteriosclerosis, Thrombosis, and Vascular Biology. 2016 ; Vol. 36, No. 10. pp. 2108-2114.
@article{05a9e8c31da94b82b722032bc908f014,
title = "Probucol in albuminuric type 2 diabetes mellitus patients on renin-angiotensin system blockade",
abstract = "Objective - To determine the effect of probucol on urine albumin excretion in type 2 diabetes mellitus patients with albuminuria using angiotensin-converting enzyme inhibitors or angiotensin receptor blockers. Approach and Results - This was a 16-week, phase II, randomized, placebo-controlled, parallel-group study in type 2 diabetes mellitus patients with a urinary albumin/creatinine ratio of ≥300 mg/g using angiotensin-converting enzyme inhibitors or angiotensin receptor blockers, conducted in 17 tertiary referral hospitals. Eligible patients were randomized to probucol 250 mg/d (n=44), probucol 500 mg/d (n=41), and placebo (n=41) groups in a ratio of 1:1:1 after block randomization procedures, keeping the treatment assignment blinded to the investigators, patients, and study assistants. The primary end point was change in the geometric mean of urinary albumin/creatinine ratio from baseline to week 16 (ClinicalTrials.gov identifier NCT01726816). The study was started on November 8, 2012, and completed on March 24, 2014. The least squares mean change±SE from baseline in urinary albumin/creatinine ratio at week 16 was -7.2±639.5 mg/g in the probucol 250 mg/d group (n=43; P=0.2077 versus placebo group), 9.3±587.4 mg/g in the probucol 500 mg/d group (n=40; P=0.1975 versus placebo group), and 259.0±969.1 mg/g in the placebo group (n=41). Although the majority of subjects were on statins, probucol treatment significantly lowered total cholesterol and low-density lipoprotein cholesterol levels. QT prolongation occurred in one and two subjects in control and probucol 250 mg/d groups, respectively. Conclusions - Four months of probucol up to 500 mg/d failed to reduce urinary albumin excretion.",
keywords = "albuminuria, antioxidants, diabetic nephropathies, probucol, type 2 diabetes mellitus",
author = "Jin, {Sang Man} and Han, {Kyung Ah} and Yu, {Jae Myung} and Sohn, {Tae Seo} and Choi, {Sung Hee} and Chung, {Choon Hee} and Park, {Ie Byung} and Rhee, {Eun Jung} and Sei-Hyun Baik and Park, {Tae Sun} and Lee, {In Kyu} and Ko, {Seung Hyun} and Hwang, {You Cheol} and Cha, {Bong Soo} and Lee, {Hyoung Woo} and Nam, {Moon Suk} and Lee, {Moon Kyu}",
year = "2016",
month = "10",
day = "1",
doi = "10.1161/ATVBAHA.116.308034",
language = "English",
volume = "36",
pages = "2108--2114",
journal = "Arteriosclerosis, Thrombosis, and Vascular Biology",
issn = "1079-5642",
publisher = "Lippincott Williams and Wilkins",
number = "10",

}

TY - JOUR

T1 - Probucol in albuminuric type 2 diabetes mellitus patients on renin-angiotensin system blockade

AU - Jin, Sang Man

AU - Han, Kyung Ah

AU - Yu, Jae Myung

AU - Sohn, Tae Seo

AU - Choi, Sung Hee

AU - Chung, Choon Hee

AU - Park, Ie Byung

AU - Rhee, Eun Jung

AU - Baik, Sei-Hyun

AU - Park, Tae Sun

AU - Lee, In Kyu

AU - Ko, Seung Hyun

AU - Hwang, You Cheol

AU - Cha, Bong Soo

AU - Lee, Hyoung Woo

AU - Nam, Moon Suk

AU - Lee, Moon Kyu

PY - 2016/10/1

Y1 - 2016/10/1

N2 - Objective - To determine the effect of probucol on urine albumin excretion in type 2 diabetes mellitus patients with albuminuria using angiotensin-converting enzyme inhibitors or angiotensin receptor blockers. Approach and Results - This was a 16-week, phase II, randomized, placebo-controlled, parallel-group study in type 2 diabetes mellitus patients with a urinary albumin/creatinine ratio of ≥300 mg/g using angiotensin-converting enzyme inhibitors or angiotensin receptor blockers, conducted in 17 tertiary referral hospitals. Eligible patients were randomized to probucol 250 mg/d (n=44), probucol 500 mg/d (n=41), and placebo (n=41) groups in a ratio of 1:1:1 after block randomization procedures, keeping the treatment assignment blinded to the investigators, patients, and study assistants. The primary end point was change in the geometric mean of urinary albumin/creatinine ratio from baseline to week 16 (ClinicalTrials.gov identifier NCT01726816). The study was started on November 8, 2012, and completed on March 24, 2014. The least squares mean change±SE from baseline in urinary albumin/creatinine ratio at week 16 was -7.2±639.5 mg/g in the probucol 250 mg/d group (n=43; P=0.2077 versus placebo group), 9.3±587.4 mg/g in the probucol 500 mg/d group (n=40; P=0.1975 versus placebo group), and 259.0±969.1 mg/g in the placebo group (n=41). Although the majority of subjects were on statins, probucol treatment significantly lowered total cholesterol and low-density lipoprotein cholesterol levels. QT prolongation occurred in one and two subjects in control and probucol 250 mg/d groups, respectively. Conclusions - Four months of probucol up to 500 mg/d failed to reduce urinary albumin excretion.

AB - Objective - To determine the effect of probucol on urine albumin excretion in type 2 diabetes mellitus patients with albuminuria using angiotensin-converting enzyme inhibitors or angiotensin receptor blockers. Approach and Results - This was a 16-week, phase II, randomized, placebo-controlled, parallel-group study in type 2 diabetes mellitus patients with a urinary albumin/creatinine ratio of ≥300 mg/g using angiotensin-converting enzyme inhibitors or angiotensin receptor blockers, conducted in 17 tertiary referral hospitals. Eligible patients were randomized to probucol 250 mg/d (n=44), probucol 500 mg/d (n=41), and placebo (n=41) groups in a ratio of 1:1:1 after block randomization procedures, keeping the treatment assignment blinded to the investigators, patients, and study assistants. The primary end point was change in the geometric mean of urinary albumin/creatinine ratio from baseline to week 16 (ClinicalTrials.gov identifier NCT01726816). The study was started on November 8, 2012, and completed on March 24, 2014. The least squares mean change±SE from baseline in urinary albumin/creatinine ratio at week 16 was -7.2±639.5 mg/g in the probucol 250 mg/d group (n=43; P=0.2077 versus placebo group), 9.3±587.4 mg/g in the probucol 500 mg/d group (n=40; P=0.1975 versus placebo group), and 259.0±969.1 mg/g in the placebo group (n=41). Although the majority of subjects were on statins, probucol treatment significantly lowered total cholesterol and low-density lipoprotein cholesterol levels. QT prolongation occurred in one and two subjects in control and probucol 250 mg/d groups, respectively. Conclusions - Four months of probucol up to 500 mg/d failed to reduce urinary albumin excretion.

KW - albuminuria

KW - antioxidants

KW - diabetic nephropathies

KW - probucol

KW - type 2 diabetes mellitus

UR - http://www.scopus.com/inward/record.url?scp=84982813090&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84982813090&partnerID=8YFLogxK

U2 - 10.1161/ATVBAHA.116.308034

DO - 10.1161/ATVBAHA.116.308034

M3 - Article

C2 - 27493100

AN - SCOPUS:84982813090

VL - 36

SP - 2108

EP - 2114

JO - Arteriosclerosis, Thrombosis, and Vascular Biology

JF - Arteriosclerosis, Thrombosis, and Vascular Biology

SN - 1079-5642

IS - 10

ER -